Brokerages Expect Seattle Genetics, Inc. (NASDAQ:SGEN) Will Announce Earnings of -$0.15 Per Share

Share on StockTwits

Brokerages expect Seattle Genetics, Inc. (NASDAQ:SGEN) to announce earnings per share of ($0.15) for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have made estimates for Seattle Genetics’ earnings, with the highest EPS estimate coming in at $2.84 and the lowest estimate coming in at ($0.65). Seattle Genetics reported earnings of ($0.54) per share in the same quarter last year, which would suggest a positive year over year growth rate of 72.2%. The company is scheduled to issue its next earnings report on Tuesday, November 3rd.

On average, analysts expect that Seattle Genetics will report full-year earnings of ($0.81) per share for the current fiscal year, with EPS estimates ranging from ($2.53) to $1.98. For the next fiscal year, analysts anticipate that the business will post earnings of ($0.21) per share, with EPS estimates ranging from ($1.44) to $0.96. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Seattle Genetics.

Seattle Genetics (NASDAQ:SGEN) last issued its earnings results on Thursday, July 30th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.58) by $0.46. Seattle Genetics had a negative return on equity of 18.32% and a negative net margin of 25.17%. The firm had revenue of $278.00 million for the quarter, compared to analysts’ expectations of $256.74 million.

SGEN has been the topic of several recent analyst reports. BMO Capital Markets boosted their price target on Seattle Genetics from $174.00 to $186.00 in a research note on Tuesday, June 30th. ValuEngine upgraded Seattle Genetics from a “hold” rating to a “buy” rating in a research note on Thursday. William Blair reiterated a “buy” rating on shares of Seattle Genetics in a research note on Thursday, July 2nd. HC Wainwright reissued a “buy” rating and issued a $200.00 price objective (up from $175.00) on shares of Seattle Genetics in a report on Friday, July 31st. Finally, BidaskClub raised Seattle Genetics from a “hold” rating to a “buy” rating in a report on Friday. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $156.26.

Shares of SGEN traded down $4.81 during midday trading on Monday, reaching $193.08. 747,892 shares of the company were exchanged, compared to its average volume of 1,160,240. The stock has a 50-day moving average price of $164.29 and a 200-day moving average price of $153.36. The company has a market cap of $33.60 billion, a price-to-earnings ratio of -127.87 and a beta of 1.26. Seattle Genetics has a 1-year low of $79.34 and a 1-year high of $200.42.

In other news, CEO Clay B. Siegall sold 28,472 shares of the company’s stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $175.08, for a total value of $4,984,877.76. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Vaughn B. Himes sold 8,000 shares of the company’s stock in a transaction on Friday, July 17th. The stock was sold at an average price of $179.42, for a total transaction of $1,435,360.00. Following the completion of the transaction, the insider now directly owns 199,840 shares in the company, valued at $35,855,292.80. The disclosure for this sale can be found here. Over the last three months, insiders have sold 174,972 shares of company stock worth $28,422,822. Company insiders own 31.10% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of SGEN. Atria Investments LLC acquired a new position in Seattle Genetics during the second quarter worth $5,602,000. Two Sigma Advisers LP acquired a new position in Seattle Genetics during the second quarter worth $3,670,000. Principal Financial Group Inc. increased its position in Seattle Genetics by 35.3% during the second quarter. Principal Financial Group Inc. now owns 119,070 shares of the biotechnology company’s stock worth $20,232,000 after buying an additional 31,044 shares during the last quarter. Garde Capital Inc. acquired a new position in Seattle Genetics during the second quarter worth $246,000. Finally, Bridgeway Capital Management Inc. increased its position in Seattle Genetics by 5.3% during the second quarter. Bridgeway Capital Management Inc. now owns 19,700 shares of the biotechnology company’s stock worth $3,347,000 after buying an additional 1,000 shares during the last quarter. 91.96% of the stock is currently owned by institutional investors and hedge funds.

Seattle Genetics Company Profile

Seattle Genetics, Inc, a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas.

See Also: Cryptocurrencies

Get a free copy of the Zacks research report on Seattle Genetics (SGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply